676 related articles for article (PubMed ID: 25203719)
1. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
[TBL] [Abstract][Full Text] [Related]
2. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Shook BC; Rassnick S; Osborne MC; Davis S; Westover L; Boulet J; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Palmer D; Reyes M; Demarest K; Tang Y; Rhodes K; Jackson PF
J Med Chem; 2010 Nov; 53(22):8104-15. PubMed ID: 20973483
[TBL] [Abstract][Full Text] [Related]
3. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF
J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465
[TBL] [Abstract][Full Text] [Related]
4. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC
Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195
[TBL] [Abstract][Full Text] [Related]
5. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
[TBL] [Abstract][Full Text] [Related]
7. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
10. 5-Substituted 2-benzylidene-1-tetralone analogues as A
Janse van Rensburg HD; Terre'Blanche G; van der Walt MM; Legoabe LJ
Bioorg Chem; 2017 Oct; 74():251-259. PubMed ID: 28881253
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Carta AR; Pinna A; Tronci E; Morelli M
Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
[TBL] [Abstract][Full Text] [Related]
12. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Zheng J; Yang Z; Li X; Li L; Ma H; Wang M; Zhang H; Zhen X; Zhang X
ACS Chem Neurosci; 2014 Aug; 5(8):674-82. PubMed ID: 24922583
[TBL] [Abstract][Full Text] [Related]
13. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.
Squarcialupi L; Colotta V; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Borea PA; Porta N; Ciancetta A; Moro S
Eur J Med Chem; 2014 Sep; 84():614-27. PubMed ID: 25063944
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A
Harmse R; van der Walt MM; Petzer JP; Terre'Blanche G
Bioorg Med Chem Lett; 2016 Dec; 26(24):5951-5955. PubMed ID: 27836398
[TBL] [Abstract][Full Text] [Related]
15. C2-substituted quinazolinone derivatives exhibit A
Pieterse L; van der Walt MM; Terre'Blanche G
Bioorg Med Chem Lett; 2020 Aug; 30(16):127274. PubMed ID: 32631506
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
Hodgson RA; Bertorelli R; Varty GB; Lachowicz JE; Forlani A; Fredduzzi S; Cohen-Williams ME; Higgins GA; Impagnatiello F; Nicolussi E; Parra LE; Foster C; Zhai Y; Neustadt BR; Stamford AW; Parker EM; Reggiani A; Hunter JC
J Pharmacol Exp Ther; 2009 Jul; 330(1):294-303. PubMed ID: 19332567
[TBL] [Abstract][Full Text] [Related]
18. Identification of a New Series of Potent Adenosine A
Yang Z; Li L; Zheng J; Ma H; Tian S; Li J; Zhang H; Zhen X; Zhang X
ACS Chem Neurosci; 2016 Nov; 7(11):1575-1584. PubMed ID: 27569066
[TBL] [Abstract][Full Text] [Related]
19. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
20. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]